Moderna, Inc. $MRNA Shares Purchased by Banco Santander S.A.

Banco Santander S.A. raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 22.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 215,894 shares of the company’s stock after buying an additional 39,056 shares during the period. Banco Santander S.A. owned approximately 0.06% of Moderna worth $5,577,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Mufg Securities Americas Inc. grew its holdings in shares of Moderna by 23.8% in the 3rd quarter. Mufg Securities Americas Inc. now owns 9,338 shares of the company’s stock worth $241,000 after acquiring an additional 1,796 shares during the last quarter. AXQ Capital LP lifted its holdings in shares of Moderna by 115.4% during the third quarter. AXQ Capital LP now owns 21,749 shares of the company’s stock valued at $562,000 after purchasing an additional 11,650 shares during the last quarter. Telemark Asset Management LLC purchased a new position in Moderna in the 3rd quarter worth about $12,915,000. NEOS Investment Management LLC raised its holdings in Moderna by 52.2% during the 3rd quarter. NEOS Investment Management LLC now owns 38,662 shares of the company’s stock worth $999,000 after buying an additional 13,258 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in Moderna by 216.3% during the 3rd quarter. GSA Capital Partners LLP now owns 38,922 shares of the company’s stock worth $1,005,000 after buying an additional 26,617 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 3.6%

MRNA stock opened at $53.57 on Friday. The company has a 50 day moving average of $41.07 and a two-hundred day moving average of $31.31. The company has a market cap of $21.16 billion, a price-to-earnings ratio of -7.37 and a beta of 1.32. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $55.20. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.79) by $0.68. The business had revenue of $678.00 million for the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. Moderna’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($2.91) earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the transaction, the director owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Stephen Hoge sold 160,009 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the transaction, the president directly owned 1,457,427 shares in the company, valued at approximately $71,180,734.68. The trade was a 9.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 184,366 shares of company stock valued at $8,531,936 over the last ninety days. Company insiders own 10.90% of the company’s stock.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: CHMP recommended marketing authorization for mCOMBRIAX, making it the first mRNA COVID‑flu combo to receive a positive EU opinion — expands Moderna’s vaccine portfolio and opens an EU commercial market for a single‑dose respiratory vaccine for older adults. Moderna gets EU regulator nod for combined COVID, flu vaccine
• Positive Sentiment: Moderna and its CEO highlighted the CHMP’s “rigorous scientific review,” a credibility boost that may ease rollout and payer discussions in Europe. After CHMP nod, Moderna CEO applauds EU’s ‘rigorous scientific review’
• Neutral Sentiment: The FDA has said it will review Moderna’s mRNA flu vaccine data, signalling a potential U.S. pathway but not an immediate approval — positive for long‑term TAM but uncertain timing. FDA to review Moderna mRNA flu vaccine
• Neutral Sentiment: Coverage notes (WSJ/The Hill) underscore the EU recommendation amid ongoing U.S. scrutiny of Moderna — regulatory wins abroad may offset domestic challenges but don’t eliminate U.S. uncertainty. Moderna’s Covid-Flu Vaccine Recommended for Approval in EU
• Negative Sentiment: Insider selling: President Stephen Hoge recently sold ~160,009 shares (disclosed filing), which some investors view as a near‑term negative signal on insider conviction. Insider Selling: Moderna President Sells 160,009 Shares

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. TD Cowen reiterated a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a research note on Tuesday, February 17th. The Goldman Sachs Group lifted their price objective on shares of Moderna from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 17th. BMO Capital Markets upgraded Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research report on Monday, January 5th. Two research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $31.87.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.